Call planned today at 8:30 a.m. (ET) to discuss company's diabetes program progression The INHALE-1 study is a 26-week, ...

Patients with COPD had slightly more major adverse cardiovascular events after initiating single-inhaler triple therapy vs a LABA-ICS inhaler.

Large numbers of hospital admissions, along with poor adherence and the prescribing of inappropriate inhalers ... In COPD, 900,000 people have been diagnosed, while another 2.1 million have ...

Major companies in the dry powder inhaler market are focusing on innovation, developing products with muscarinic antagonists for the treatment of chronic obstructive pulmonary disease (COPD), and ...

3. Experts Explore Barriers to Diversity in Respiratory Medicine ... for COPD Two abstracts presented at ATS 2024 ...

2 Department of Medicine, Division of Pulmonary, Critical Care and Sleep Disorders Medicine, University of Louisville, Kentucky, USA 3 Department of Medicine ... uea.ac.uk Background The effect of ...

Cipla to introduce Afrezza, an inhaled insulin for diabetes, offering convenience but not advised for lung-related concerns.

relief of symptoms won’t be experienced until one or two weeks after starting the treatment. Fluticasone is a prescription corticosteroid for long-term treatment of respiratory disorders, such as ...

Teva has launched new digital inhaler and drug combination in the US, containing built-in sensors that connect to a phone to help manage asthma and COPD symptoms. Israel-based Teva said the ...

Inhalers and nebulizers play a key role in delivering medication to the lungs, making it easier for people with breathing ...

The role of combination therapy is explored for the treatment of COPD. December 14th 2022EP. 5: Implementing Inhaled Corticosteroids (ICS) into COPD Patient Treatment Regimen Inhaled ...